You are here: Industry Insights > Protagonist Therapeutics

News List

Hepcidin Mimetic Candidate Receives Fast Track Designation for Polycythemia Vera americanpharmaceuticalreview
December 23, 2020
Protagonist Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PTG-300 in the treatment of polycythemia vera, a rare disease characterized by the excessive production of red blood cells. PTG-300 is ...
Protagonist Announces Phase 2 Results for Polycythemia Vera Treatment americanpharmaceuticalreview
May 13, 2020
Protagonist Therapeutics announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera.
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists firstwordpharma
May 09, 2019
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class ...
Protagonist Therapeutics Announces Fast Track Designation of Hepcidin Mimetic PTG-300 americanpharmaceuticalreview
September 28, 2018
Protagonist Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia.